1. Cancer Biology
  2. Cell Biology
Download icon

Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion

Research Article
  • Cited 0
  • Views 268
  • Annotations
Cite this article as: eLife 2021;10:e66721 doi: 10.7554/eLife.66721

Abstract

Pancreatic cancer has a high mortality rate due to metastasis. Whereas KRAS is mutated in most pancreatic cancer patients, controlling KRAS or its downstream effectors has not been succeeded clinically. ARL4C is a small G protein whose expression is induced by the Wnt and EGF-RAS pathways. In the present study, we found that ARL4C is frequently overexpressed in pancreatic cancer patients and showed that its localization to invasive pseudopods is required for cancer cell invasion. IQGAP1 was identified as a novel interacting protein for ARL4C. ARL4C recruited IQGAP1 and its downstream effector, MMP14, to invasive pseudopods. Specific localization of ARL4C, IQGAP1, and MMP14 was the active site of invasion, which induced degradation of the extracellular matrix. Moreover, subcutaneously injected antisense oligonucleotide against ARL4C into tumor-bearing mice suppressed metastasis of pancreatic cancer. These results suggest that ARL4C-IQGAP1-MMP14 signaling is activated at invasive pseudopods of pancreatic cancer cells.

Data availability

-Sequencing data have been deposited in DDBJ under accession codes DRA011537.-All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1-7, Figure 2-figure supplement 1, Figure 2-figure supplement 2, Figure 2-figure supplement 3, Figure 3-figure supplement 1, Figure 3-figure supplement 2, Figure 4-figure supplement 1, Figure 6-figure supplement 1, Figure 7-figure supplement 1, Supplementary File 1 Table 1, and Supplementary File 1 Table 2.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Akikazu Harada

    Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Osaka University, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  2. Shinji Matsumoto

    Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Osaka University, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  3. Yoshiaki Yasumizu

    Laboratory of Experimental Immunology, WPI Frontier Immunology Research Center, Osaka University, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9872-4909
  4. Toshiyuki Akama

    Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Osaka University, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  5. Hidetoshi Eguchi

    Gastrointestinal Surgery, Osaka University, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  6. Akira Kikuchi

    Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Osaka University, Suita, Japan
    For correspondence
    akikuchi@molbiobc.med.osaka-u.ac.jp
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3378-9522

Funding

Ministry of Education, Culture, Sports, Science and Technology (16H06374)

  • Akira Kikuchi

Ministry of Education, Culture, Sports, Science and Technology (18H04861)

  • Akira Kikuchi

Ministry of Education, Culture, Sports, Science and Technology (18H05101)

  • Akira Kikuchi

Yasuda Memorial Medical Foundation

  • Akira Kikuchi

Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care

  • Akira Kikuchi

Osaka University

  • Akira Kikuchi

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All protocols used for the animal experiments in this study were approved by the Animal Research Committee of Osaka University, Japan (No. 26-032-048). This information is mentioned in the 'Materials and Methods' section.

Reviewing Editor

  1. Lynne-Marie Postovit, University of Alberta, Canada

Publication history

  1. Received: January 20, 2021
  2. Accepted: September 29, 2021
  3. Accepted Manuscript published: September 30, 2021 (version 1)

Copyright

© 2021, Harada et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 268
    Page views
  • 50
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Cancer Biology
    2. Cell Biology
    Brian Spurlock et al.
    Short Report Updated

    Gene knockout of the master regulator of mitochondrial fission, Drp1, prevents neoplastic transformation. Also, mitochondrial fission and its opposing process of mitochondrial fusion are emerging as crucial regulators of stemness. Intriguingly, stem/progenitor cells maintaining repressed mitochondrial fission are primed for self-renewal and proliferation. Using our newly derived carcinogen transformed human cell model, we demonstrate that fine-tuned Drp1 repression primes a slow cycling ‘stem/progenitor-like state’, which is characterized by small networks of fused mitochondria and a gene-expression profile with elevated functional stem/progenitor markers (Krt15, Sox2 etc) and their regulators (Cyclin E). Fine tuning Drp1 protein by reducing its activating phosphorylation sustains the neoplastic stem/progenitor cell markers. Whereas, fine-tuned reduction of Drp1 protein maintains the characteristic mitochondrial shape and gene-expression of the primed ‘stem/progenitor-like state’ to accelerate neoplastic transformation, and more complete reduction of Drp1 protein prevents it. Therefore, our data highlights a ‘goldilocks’ level of Drp1 repression supporting stem/progenitor state dependent neoplastic transformation.

    1. Cancer Biology
    Luca Tirinato et al.
    Research Article Updated

    Although much progress has been made in cancer treatment, the molecular mechanisms underlying cancer radioresistance (RR) as well as the biological signatures of radioresistant cancer cells still need to be clarified. In this regard, we discovered that breast, bladder, lung, neuroglioma, and prostate 6 Gy X-ray resistant cancer cells were characterized by an increase of lipid droplet (LD) number and that the cells containing highest LDs showed the highest clonogenic potential after irradiation. Moreover, we observed that LD content was tightly connected with the iron metabolism and in particular with the presence of the ferritin heavy chain (FTH1). In fact, breast and lung cancer cells silenced for the FTH1 gene showed a reduction in the LD numbers and, by consequence, became radiosensitive. FTH1 overexpression as well as iron-chelating treatment by Deferoxamine were able to restore the LD amount and RR. Overall, these results provide evidence of a novel mechanism behind RR in which LDs and FTH1 are tightly connected to each other, a synergistic effect that might be worth deeply investigating in order to make cancer cells more radiosensitive and improve the efficacy of radiation treatments.